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pelvis from imaging. There were no significant differences in 
bladder dose. The magnitude of benefit of daily imaging for a 
patient could not be predicted by characteristics on planning 
CT scan. 
 
Conclusions: Daily online CBCT verification imaging improves 
CTV coverage and reduces dose to rectum during IGRT for 
prostate cancer.  
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Purpose/Objective: This study aimed to investigate the 
impact of increasing radiation delivery time on the outcome 
of hypofractionated radiation therapy for prostate cancer. 
Intrafraction repair is seldom discussed in relation to external 
beam radiation therapy as most fractional doses are 
delivered in the course of a few minutes and the beam-on 
time is not very much different from the time to deliver all 
individual fields. Advanced techniques aimed at delivering 
high fractional dose, employing multiple fields, scanning the 
target volume or requiring multiple imaging sessions may 
however take considerably longer, increasing the importance 
of intrafraction repair. 
Materials and Methods: Mono-exponential and bi-exponential 
repair models have been used in prostate patients to study 
the loss of biologically effective dose for several clinically-
relevant irradiation times between 5 and 60 minutes. These 
were then converted into loss of biochemical control at 5 
years using clinically-relevant dose response curves derived 
from 10688 prostate patients treated with conventional 
fractionation. The theoretical predictions were subsequently 
compared with clinical results from 14 newly reported studies 
totalling 4363 patients undergoing conventionally-
fractionated and hypofractionated prostate radiotherapy. 
Results: For low-risk patients the equivalent doses delivered 
were quite high and consequently the reported results were 
very good and in agreement with theoretical predictions. For 
intermediate- and high-risk patients however, the results 
from hypofractionated schedules delivered with time-
consuming techniques appear to be compatible with 
predictions accounting for intrafraction repair taking place 
during longer irradiations, while results from moderately 
hypofractionated or conventionally-fractionated schedules 
are in agreement with short irradiation times. Treatment 
sessions lasting more than about 20 minutes could lead to 
significant loss of biochemical control even when relatively 
slow repair is relevant for prostate tumours. Large effect 
losses could therefore be expected from extremely 
hypofractionated schedules with long irradiation sessions as 
might be the case of scanned beams and/or with multiple 
intrafraction imaging sessions to check the positioning of the 
patient. The loss of effect might also be reflected into an 
apparent reduced sensitivity to fractionation for the tumours. 
Conclusions: Intrafraction repair plays an important role for 
prostate radiation therapy and may lead to loss of biological 
effect in the case of extremely hypofractionated techniques 
requiring increased irradiation times Neglecting intrafraction 
could also interfere with the derivation of the fractionation 
sensitivity for prostate tumours.  
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Purpose/Objective: To test the hypothesis that implantation 
of a hydrogel rectum spacer in patients with prostate cancer 
undergoing intensity modulated radiation therapy (IMRT) 
reduces predicted probabilities for grade 2-3 (Gr2-3) acute 
and late rectal toxicities. 
Materials and Methods: In 26 patients with localized prostate 
cancer (low-risk:8/26(31%); intermediate-risk: 11/26 (42%); 
high-risk: 7/26 (27%)), a hydrogel spacer (SpaceOAR®, 
Augmenix) was injected under transrectal ultrasound 
guidance in Denonvilliers’ space between the prostate and 
the rectal wall. IMRT treatment plans (78 Gy in 39 fractions) 
were designed based on CT scans acquired before (IMRT-pre) 
and after (IMRT-post) hydrogel injection. Published 
nomograms based on clinical risk factors (use of 
anticoagulantia, hormonal therapy, and anti-hypertensives, 
presence of diabetes, haemorrhoids, pre-EBRT abdominal 
surgery) and dose-volume histogram (DVH) parameters (V40Gy, 
V75Gy) were used to estimate predicted probabilities for Gr2-3 
acute gastro-intestinal (GI) toxicity1, Gr2-3 late rectal 
bleeding (LRB)2, and Gr2-3 fecal incontinence (FI)2 for IMRT-
